To support the development and application of tools that would enable the monitoring in real-time of the dynamic three-dimensional structure of mammalian genomes and provide insight into how organizing components of 4D genome architecture affect biological processes in live cells.
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function system development and function; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. Each P01 application submitted to this FOA must include at least two related research projects that share a common central theme, focus, and/or overall objective.
The purpose of this award is to support phased transition of outstanding graduate students from groups underrepresented in the biomedical, clinical, behavioral and social sciences research enterprise from graduate work to postdoctoral research positions in Dental, Oral, and Craniofacial (DOC) research. The first phase (F99) will support the final two years of graduate research training for individuals in PhD or dual degree clinician scientist programs. Following graduation and attainment of a postdoctoral research position, the second phase (K00) will provide support for up to three years of mentored postdoctoral research.
The NIAID New Innovator Awards supports post-doctoral and early stage investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce a major impact on broad, important problems in biomedical research of priority to NIAID. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.
Drug development tools (DDTs) are methods, materials, or measures that can potentially facilitate drug development. To support DDT development efforts, FDA established qualification programs for animal models for use under the Animal Rule, biomarkers, and clinical outcome assessments. Examples of DDTs may include but are not limited to: a biomarker used for clinical trial enrichment, a clinical outcome assessment (COA) used to evaluate clinical benefit, or an animal model used for efficacy testing of medical countermeasures under the regulations commonly referred to as the Animal Rule.
This Funding Opportunity Announcement (FOA) encourages solicits applications that propose research designed to test training, mentoring, and networking interventions intended to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the design and implementation of potential interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.
This Funding Opportunity Announcement (FOA) invites qualified academic institutions to apply for support to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and nonprofit private institutions of higher education. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity. The goal of this FOA is to upgrade or create novel biomedical research infrastructure to strengthen biomedical research programs. The proposed project must serve the applicant-defined institution-wide biomedical research needs. Each project is expected to provide long-term improvements to the institutional research infrastructure. Targeted are the modernization of core facilities and the development of other infrastructure serving an institution-wide research community on a shared basis.
The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research projects that examine the relative biological effectiveness (RBE) of high linear energy transfer (high LET) radiation on cell and tissue targets. The overall goal of the research is to establish a firm scientific basis for RBE models of high LET radiation and determine potential benefits in cancer treatment. A meritorious application is expected to be well-balanced in terms of interdisciplinary science that spans approaches in both radiation biology and radiation physics research. Priorities for this FOA are on 1) Applications with potential to enhance the understanding of mechanisms related to high LET effects in both cancer and normal tissues; and 2) Characterization of high LET effects that have potential to inform treatment strategies for cancers resistant to conventional radiation or other combined modality treatments.
This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH.
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that propose to establish Offices of Sponsored Programs (OSPs) or enhance the services of existing OSPs or similar entities at domestic institutions of higher learning. Program priorities include funding primarily undergraduate institutions with emerging biomedical research and/or undergraduate research training programs.
This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's Disease (AD) and AD Related Dementias (ADRD) in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.
The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 "NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue" and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.
This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.
The purpose of this FOA is to support the NIGMS Human Genetic Cell Repository (HGCR). The repository will maintain the current collection of cell cultures and DNA samples and will acquire, characterize, and expand high-quality cell samples, and distribute cell lines and DNA isolated from them to qualified biomedical researchers.
The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.
The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.
The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.
To establish a rare disease consortium focusing on clinical outcome assessments appropriate for use in drug development to demonstrate clinical benefit.
This Funding Opportunity Announcement (FOA) invites qualified academic institutions to apply for support to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and nonprofit private institutions of higher education. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged.
